Fabrication of Mupirocin-Loaded Nanostructured Lipid Carrier and Its In Vitro Characterization
In the present study, mupirocin (MP), an antimicrobial agent, was formulated as a nanostructured lipid carrier (NLC) by using a novel method named as melt emulsion ultrafiltration method. For the formulation of NLC, glyceryl monostearate and watermelon seed oil were used as solid and liquid lipids, respectively. The method was optimized for various parameters by Taguchi design of experiment and prepared NLCs were characterized for particle size, polydispersity index (PDI), shape, zeta potential, % drug loading, and in vitro release profile. The optimized NLCs were found to be smooth, monodisperse with PDI 0.229 ± 0.093. NLCs were found to have an average particle size of 139 ± 0.75 nm and +21.9 ± 0.98 mV as zeta potential. The % drug loading of optimized NLCs was found to be 59% ± 0.13%. The optimized NLCs were able to release the drug up to 24 h. The release kinetic study revealed mixed-order kinetics. Hence, it was concluded that the novel method is simple and able to fabricate MP-loaded NLCs with sustained release property and being stable in terms of particle size, PDI, and % drug loading..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Assay and drug development technologies - 19(2021), 4 vom: 07. Mai, Seite 216-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Alok Pratap [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/adt.2020.1070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323369138 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323369138 | ||
| 003 | DE-627 | ||
| 005 | 20231225184030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/adt.2020.1070 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323369138 | ||
| 035 | |a (NLM)33781090 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Alok Pratap |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fabrication of Mupirocin-Loaded Nanostructured Lipid Carrier and Its In Vitro Characterization |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the present study, mupirocin (MP), an antimicrobial agent, was formulated as a nanostructured lipid carrier (NLC) by using a novel method named as melt emulsion ultrafiltration method. For the formulation of NLC, glyceryl monostearate and watermelon seed oil were used as solid and liquid lipids, respectively. The method was optimized for various parameters by Taguchi design of experiment and prepared NLCs were characterized for particle size, polydispersity index (PDI), shape, zeta potential, % drug loading, and in vitro release profile. The optimized NLCs were found to be smooth, monodisperse with PDI 0.229 ± 0.093. NLCs were found to have an average particle size of 139 ± 0.75 nm and +21.9 ± 0.98 mV as zeta potential. The % drug loading of optimized NLCs was found to be 59% ± 0.13%. The optimized NLCs were able to release the drug up to 24 h. The release kinetic study revealed mixed-order kinetics. Hence, it was concluded that the novel method is simple and able to fabricate MP-loaded NLCs with sustained release property and being stable in terms of particle size, PDI, and % drug loading. | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a melt emulsion ultrafiltration | |
| 650 | 4 | |a mupirocin | |
| 650 | 4 | |a nanostructured lipid carriers | |
| 650 | 4 | |a watermelon seed oil | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Glycerides |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Plant Oils |2 NLM | |
| 650 | 7 | |a glyceryl monostearate |2 NLM | |
| 650 | 7 | |a 230OU9XXE4 |2 NLM | |
| 650 | 7 | |a Mupirocin |2 NLM | |
| 650 | 7 | |a D0GX863OA5 |2 NLM | |
| 700 | 1 | |a Sharma, Satish Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Gaur, Praveen Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Dinesh Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Assay and drug development technologies |d 2002 |g 19(2021), 4 vom: 07. Mai, Seite 216-225 |w (DE-627)NLM14784164X |x 1557-8127 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:4 |g day:07 |g month:05 |g pages:216-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/adt.2020.1070 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 4 |b 07 |c 05 |h 216-225 | ||